Headquartered in 33 Broadwick Street, London·Fiscal year ends December·NASDAQ: CMPS·compasspathways.com
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a pre-revenue biotechnology company developing new treatments for mental health conditions. Its lead asset is COMP360, a proprietary, investigational, synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).
In TRD, COMP360 has completed two positive Phase 3 trials (COMP005 and COMP006). The company describes this as the world's largest classic psychedelic clinical program in TRD. COMP360 holds FDA Breakthrough Therapy designation, UK Innovative Licensing and Access Pathway (ILAP) designation for TRD, and a Commissioner's National Priority Voucher. A rolling NDA submission is nearing completion, and the company expects a U.S. commercial launch in the first half of 2027, subject to FDA approval.
Compass is building commercial capabilities in provider training, market access, reimbursement, supply chain and patient support. It plans to deliver COMP360 through the existing network of more than 8,500 treatment centers equipped for multi-hour treatments. The company targets an estimated 4 million U.S. TRD patients. It is also running a registration-enabling late-stage PTSD trial and collaborating with the U.S. Department of Veterans Affairs on a trial in veterans. Updated
Pre-Market Stock Futures: Futures are trading lower as we start off the new week, as oil surges higher amid reports that a U.S. warship was turned back in the Strait of Hormuz,…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Wednesday's top analyst upgrades and downgrades included AppLovin, Arista Networks, Charles Schwab, First Solar, Global Payments, Halliburton, Monster Beverage, NXP Semiconductor, QuantumScape, Union Pacific and Welltower.
Compass Pathways plc (Nasdaq: CMPS) is a pre-revenue biotechnology company developing new treatments for mental health conditions. Its lead asset is COMP360, a proprietary, investigational, synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).
What is the CMPS stock price target?
The Wall Street consensus 12-month price target for CMPS is $23.31.